Conflict of Interest Disclosures: Dr Lin reported receiving nonfinancial support from Seagen for manuscript preparation during the conduct of the study; grants from Genentech, Merck, AstraZeneca, Zion Pharmaceuticals, Seagen, Olema Pharmaceuticals, and Pfizer outside the submitted work; personal fees from Pfizer, Puma, Seagen, Daiichi Sankyo, Prelude Therapeutics, Denali Therapeutics, Olema Pharmaceuticals, AstraZeneca, Aleta BioPharma, Affinia Therapeutics, and Voyager Therapeutics outside the submitted work; consulting fees from Affinia Therapeutics, Aleta BioTherapeutics, AstraZeneca, Daiichi Sankyo, Denali Therapeutics, Olema Oncology, Pfizer, Prelude Therapeutics, Seagen, Voyager Therapeutics, and Artera Inc; and royalties from UpToDate outside the submitted work. Dr Murthy reported receiving grants from Seagen, Oncothyreon, and Cascadian Therapeutics during the conduct of the study; consulting fees and nonfinancial support for manuscript writing and travel from Seagen during the conduct of the study; grants from Genentech/Roche, Pfizer, Daiichi Sankyo, AstraZeneca, and EMD Serono outside the submitted work; and consulting fees from Novartis, AstraZeneca, Pfizer, Genentech/Roche, Puma, and Sanofi outside the submitted work. Dr Abramson reported serving on the advisory boards of Eisai, Seagen, and Daiichi Sankyo outside the submitted work; receiving consulting fees from AstraZeneca and Daiichi Sankyo; and receiving research funding from Genentech and Lilly. Dr Anders reported receiving grants from Seagen during the conduct of the study; consulting fees from Genentech, Eisai, Ipsen, Seagen Inc, AstraZeneca, Novartis, Immunomedics, Elucida Oncology, and Athenex outside the submitted work; grants from PUMA, Lilly, Merck, Nektar, Tesaro, G1 Therapeutics, Zion Pharma, Novartis, Pfizer, AstraZeneca, and Elucida outside the submitted work; and royalties from Jones and Bartlett and UptoDate.com outside the submitted work; and participating in an education program with Eisai. Dr Bachelot reported receiving consulting fees from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer, Roche, and Seagen; grants from AstraZeneca, Daiichi Sankyo, Novartis, Pfizer, Roche, and Seagen; and nonfinancial support from Pfizer outside the submitted work. Dr Bedard reported receiving grants from Seagen during the conduct of the study; grants from Amgen, Bicara, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline, Genentech/Roche, Novartis, Merck, Lilly, Seagen, Zymeworks, Pfizer, Medicenna, Nektar Therapeutics, Immunomedics, and Sanofi outside the submitted work; nonfinancial consulting relationship with Seagen, Lilly, Amgen, Merck, Gilead Sciences, Bristol Myers Squibb, and Pfizer; and serving in an uncompensated advisory capacity for Amgen, Lilly, Seagen, Zymeworks, Gilead, and Merck. Dr Borges reported receiving consulting fees and grants from Seagen during the conduct of the study; personal fees from AstraZeneca outside the submitted work; and grants from AstraZeneca, Olema Oncology, and Oncosec Medical; and having equity ownership in PERLATX. Dr Cameron reported receiving consulting fees from Novartis, Roche, and Seagen; receiving grants from AstraZeneca, Daiichi-Sankyo, GlaxoSmithKline, Novartis, Roche, and Seagen; and serving on the Independent Data Monitoring Committee for Synthon outside the submitted work. Dr Carey reported receiving research funding from Syndax Pharmaceuticals, Novartis, NanoString Technologies, AbbVie, Seagen, and Veracyte; having uncompensated relationships with Eisai, Sanofi-Aventis, Novartis, G1 Therapeutics, Genentech/Roche, GlaxoSmithKline, AstraZeneca/Daiichi Sankyo, Aptitude Health, and Exact Sciences; and having an immediate family member with a royalty-sharing agreement and investorship interest in licensed intellectual property to Falcon Therapeutics. Dr Chien reported receiving grants from Seagen during the conduct of the study; grants from Amgen, Merck, Puma Biotechnology, and Seagen; and grants from Merck, Amgen, and Puma paid to her institution outside the submitted work. Dr Curigliano reported serving on the advisory boards of Roche, Daiichi Sankyo, AstraZeneca, Lilly, Novartis, Pfizer, Celcuity, Exact Sciences, Ellipsis, Bristol Myers Squibb, Seagen, Merck, Menarini, and Gilead; receiving consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Foundation Medicine, GlaxoSmithKline, Lilly, Novartis, Pfizer, Roche/Genentech, Samsung, and Seagen; receiving honoraria from Ellipses Pharma; receiving reimbursement for travel expenses from Pfizer and Roche/Genentech; serving on a speakers bureau for Daiichi Sankyo, Foundation Medicine, Lilly, Novartis, Pfizer, Roche/Genentech, Samsung, and Seagen; and receiving grants from Daiichi Sankyo and Merck outside the submitted work. Dr DiGiovanna reported receiving royalties from Dako and NeoMarkers; and grants from Cascadian Therapeutics, Genentech, and Seagen to conduct clinical research at Yale University. Dr Gelmon reported receiving consulting fees from AstraZeneca, Ayala Pharmaceuticals, Lilly, Merck, Mylan, Novartis, Pfizer, Roche, and Seagen outside the submitted work; serving on an advisory board for Gilead Sciences; and serving on a speakers bureau for AstraZeneca and Novartis. Dr Hortobagyi reported receiving grants from Seagen during the conduct of the study, consulting fees from Novartis outside the submitted work, and grants from Novartis. Dr Hurvitz reported having equity ownership in NKMax; receiving grants from Seagen during the conduct of the study; receiving grants from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, CytomX, Daiichi Sankyo, Dantari, Digitana, Genentech/Roche, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Orinove, Pfizer, Phoenix Molecular Designs Ltd, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Samumed, Sanofi, Seagen, and Zymeworks; and receiving reimbursement for travel expenses from Lilly outside the submitted work. Dr Krop reported receiving consulting fees from Bristol Myers Squibb, Context Therapeutics, Daiichi Sankyo, Genentech/Roche, Ionis Pharmaceuticals, MacroGenics, Merck, Novartis, Seagen, and Taiho Pharmaceuticals; receiving grants from Seagen paid to his institution during the conduct of the study; receiving honoraria from AstraZeneca and Genentech/Roche; receiving grants from Pfizer, MacroGenics, and Genentech/Roche; receiving personal fees from AstraZeneca, Daiichi Sankyo, MacroGenics, Genentech/Roche, Seagen, Merck, and Novartis outside the submitted work; and being an employee and equity owner of Freeline Therapeutics and PureTech Health. Dr Loi reported receiving research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics, AstraZeneca, and Seagen. She has acted as consultant (not compensated) to Seagen, Novartis, Bristol Meyers Squibb, Merck, AstraZeneca, Eli Lilly, Pfizer, Gilead Therapeutics, and Roche-Genentech. She has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, AstraZeneca, Silverback Therapeutics, G1 Therapeutics, PUMA Biotechnologies, Pfizer, Gilead Therapeutics, Seagen, Daiichi Sankyo, Merck, Amunix, Tallac Therapeutics, Eli Lilly, and Bristol Meyers Squibb. Dr Loi is supported by National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York. Dr Loibl reported receiving assistance from Seagen with manuscript preparation during the conduct of the study; receiving consulting fees from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, EirGenix, GlaxoSmithKline, Gilead Sciences, Lilly, Merck, Novartis, Pfizer, Pierre Fabre, Seagen, Sanofi, and Roche; receiving honoraria from AbbVie, Amgen, AZ, Celgene/Bristol Meyers Squibb, DSI, Immunomedics/Gilead, Novartis, Pfizer, Roche, EirGenix, GlaxoSmithKline, Lilly, Mercl kGA, Pierre Fabre, Seagen, and Sanofi outside the submitted work; receiving research funding from AbbVie, AstraZeneca, Celgene, Daiichi Sankyo, Gilead, Novartis, Pfizer, and Roche; holding a patent for VM Scope GmbH with royalties paid to her institution; holding pending patents (EP14153692.0, EP21152186.9, EP15702464.7, and EP19808852.8); and being an employee of GBG Forschungs GmbH. Dr Mueller reported receiving personal fees from Seagen during the conduct of the study; receiving honoraria from Amgen, AstraZeneca, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Pfizer, MSD, Medac, Novartis, Roche, Teva, Seagen, Onkowissen, high5 Oncology, Medscape, Gilead, Pierre Fabre, and Medscape; receiving consulting fees from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, Sanofi, Seagen, Gilead, and Pierre Fabre; receiving grants from Novartis, Roche, Seagen, and Genentech; receiving grants from Roche, Pfizer, Daiichi Sankyo, and Gilead outside the submitted work; and serving on speakers bureaus for Amgen, AstraZeneca, Daiichi Sankyo, Eisai, GlaxoSmithKline, MSD, Novartis, Pfizer, Roche, Seagen Inc, Gilead, and Onkowissen.de. Dr Oliveira reported receiving grants from Seagen during the conduct of the study; receiving consulting fees from Roche, GlaxoSmithKline, Gilead, Puma Biotechnology, AstraZeneca, iTeos Therapeutics, Pierre Fabre, and MSD; receiving research funding from AstraZeneca, Genentech, Roche, Novartis, Immunomedics, Seagen, GlaxoSmithKline, Boehringer Ingelheim, Puma Biotechnology, and Zenith Epigenetics; receiving honoraria from Roche, Seagen, Novartis, AstraZeneca, and Eisai; receiving travel grants from Roche, Pierre Fabre, Novartis, and Eisai outside the submitted work; and being a member of the SOLTI executive board and scientific committee. Dr Paplomata reported receiving grants from Seagen during the conduct of the study; receiving personal fees from ICON Plc and OncLive; receiving consulting fees from Mylan, Novartis, Pfizer, Puma Biotechnology, R-pharm, and Biotheranostics; receiving honoraria from Mylan, Novartis, Pfizer, Puma, and R-pharm; receiving research funding from AbbVie, Cascadian Therapeutics, Corcept Therapeutics, Genentech, Hoosier Cancer Research Network, ImmunoGen, Merck, Novartis, Seagen Inc, and Immunogenicity; receiving reimbursement for travel expenses from Amgen, Genentech, Merck, Novartis, and Tesaro; receiving nonfinancial support from Tesaro; receiving nonfinancial support from Amgen outside the submitted work; and serving on a speakers bureau for OncLive Clinical Congress Consultants. Dr Pegram reported serving on the steering committee for Seagen during the conduct of the study and receiving consulting fees from Seagen and Roche/Genentech outside the submitted work. Dr Slamon reported receiving consulting fees from Lilly, Novartis, Pfizer, and Seagen; having equity ownership in Amgen, BioMarin Pharmaceutical, MSD, Pfizer, Seagen, 1200 Pharma, TORL BioTherapeutics, and Vertex Pharmaceuticals; receiving honoraria from Novartis; receiving research funding from Novartis, Pfizer, and Seagen; receiving reimbursement for travel expenses from BioMarin Pharmaceutical, Novartis, and Pfizer; serving on the advisory board for BioMarin Pharmaceutical; serving on the speakers bureau for Novartis; and founding 1200 Pharma and TORL BioTherapeutics outside the submitted work. Dr Zelnak reported receiving personal fees from Seagen during the conduct of the study; consulting fees from AstraZeneca, Gilead Sciences, Immunomedics, Novartis, Pfizer, and Puma Biotechnology; and personal fees from Gilead, AstraZeneca, Novartis, and Puma Biotechnology outside the submitted work. Dr Ramos reported being an employee of Seagen and receiving equity. Dr Feng reported being an employee of Seagen and receiving equity. Dr Winer reported receiving consulting fees from Carrick Therapeutics, Genentech/Roche, GlaxoSmithKline, and Jounce Therapeutics; honoraria from Carrick Therapeutics, Genentech/Roche, Genomic Health, GlaxoSmithKline, Jounce Therapeutics, and Leap Therapeutics; and research funding from Genentech/Roche outside the submitted work. No other disclosures were reported.
